Tribunal dismisses Boehringer Ingelheim's liability claim against Sanofi in Zantac case
French pharma giant Sanofi is not on the hook to indemnify Boehringer Ingelheim for potential liabilities related to ongoing Zantac litigation in the US, an International Chamber of Commerce tribunal has ruled.
The tribunal dismissed a claim brought by Boehringer Ingelheim seeking indemnification for potential losses, Sanofi announced on Tuesday. The dispute traces back to 2017, when Sanofi acquired the rights to the over-the-counter heartburn med Zantac from Boehringer Ingelheim. About two years later, the FDA issued a warning that some ranitidine medicines, including over-the-counter Zantac, contain low levels of a probable carcinogen called N-nitrosodimethylamine (NDMA).
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.